About nkarta inc - NKTX
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
NKTX At a Glance
Nkarta, Inc.
1150 Veterans Boulevard
South San Francisco, California 94080
| Phone | 1-925-407-1049 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -104,084,000.00 | |
| Sector | Health Technology | Employees | 108 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NKTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.421 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.562 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -1.213 |
NKTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -963,740.741 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NKTX Liquidity
| Current Ratio | 12.688 |
| Quick Ratio | 12.688 |
| Cash Ratio | 12.408 |
NKTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -22.664 |
| Return on Equity | -28.90 |
| Return on Total Capital | -26.774 |
| Return on Invested Capital | -24.092 |
NKTX Capital Structure
| Total Debt to Total Equity | 24.468 |
| Total Debt to Total Capital | 19.658 |
| Total Debt to Total Assets | 18.313 |
| Long-Term Debt to Equity | 22.262 |
| Long-Term Debt to Total Capital | 17.886 |